Skip to main content
. 2022 Jan 11;10(1):e003831. doi: 10.1136/jitc-2021-003831

Table 2.

Summary of response and survival data

Variables All patients
N=37
Best overall response, n (%)
 Complete response 0
 Partial response 9 (24.3)
 Stable disease ≥6 weeks 11 (29.7)
 Progressive disease 17 (45.9)
 Not evaluable 0
ORR, % (95% CI) 24.3 (11.8 to 41.2)
DCR, % (95% CI) 54.1 (36.9 to 70.5)
Time to response, months, median (range) 2.1 (1.8 to 4.1)
Duration of response, months, median (95% CI) 4.1 (1.9 to 6.3)
Progression-free survival, months, median (95% CI) 4.1 (2.1 to 5.7)
Overall survival, months, median (95% CI) 18.9 (10.8 to NR)
 6-month rate (95% CI) 89.2 (73.7 to 95.8)
 9-month rate (95% CI) 78.4 (61.4 to 88.5)
 12-month rate (95% CI) 67.2 (49.4 to 79.9)

DCR, disease control rate; NR, not reached; ORR, objective response rate.